Literature DB >> 17827837

Circulating IL-12 p40 is increased in the patients with sarcoidosis, correlation with clinical markers.

Masahiro Hata1, Katsunori Sugisaki, Eishi Miyazaki, Toshihide Kumamoto, Tomiyasu Tsuda.   

Abstract

OBJECTIVE: Sarcoidosis is considered to be provocated by highly activated Th1 lymphocytes. Because interleukin 12 (IL-12) is one of the most important cytokines for promoting Th1 reaction, we tried to detect IL-12 and its ligand IL-12 receptor in sarcoidosis patients. PATIENTS AND METHODS: We measured the serum concentration of IL -12 p40 and IL-12 p70 by ELISA method with serum obtained from 60 sarcoidosis patients, and compared the serum concentration of IL-12 p40 with other clinical markers of disease activity. Next, we examined mRNA production of IL-12 p35, IL-12 p40, IL-12Rbeta1, and IL-12beta2 of sarcoid lymph nodes with semi-quantitative RT-PCR method.
RESULTS: First, we showed that circulating IL-12 p40 was highly increased in sarcoidosis patients and was related to various other clinical markers. In particular, it was correlated with the number of involved organs which means systemic disease expansion. Second, we showed that the mRNA expression of IL-12 p40 and IL-12 receptor beta2 subunit was increased in sarcoid lymph nodes.
CONCLUSION: Our data suggest that increased circulating IL-12 p40 is an important systemic marker for disease activity, and it reflects the increased interaction between Il-12 and its ligand IL-12R in sarcoid lesions of involved organs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17827837     DOI: 10.2169/internalmedicine.46.6278

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  11 in total

1.  Dual Inhibition of Rip2 and IRAK1/4 Regulates IL-1β and IL-6 in Sarcoidosis Alveolar Macrophages and Peripheral Blood Mononuclear Cells.

Authors:  Jaya Talreja; Harvinder Talwar; Nisar Ahmad; Ruchi Rastogi; Lobelia Samavati
Journal:  J Immunol       Date:  2016-07-11       Impact factor: 5.422

2.  Mathematical model of sarcoidosis.

Authors:  Wenrui Hao; Elliott D Crouser; Avner Friedman
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-27       Impact factor: 11.205

3.  In vitro and in vivo reactivity to fungal cell wall agents in sarcoidosis.

Authors:  M Terčelj; S Stopinšek; A Ihan; B Salobir; S Simčič; B Wraber; R Rylander
Journal:  Clin Exp Immunol       Date:  2011-10       Impact factor: 4.330

4.  Dysregulation of p38 and MKP-1 in response to NOD1/TLR4 stimulation in sarcoid bronchoalveolar cells.

Authors:  Ruchi Rastogi; Wenjin Du; Donhong Ju; Gaila Pirockinaite; Yusen Liu; Gabriel Nunez; Lobelia Samavati
Journal:  Am J Respir Crit Care Med       Date:  2010-09-17       Impact factor: 21.405

5.  Minocycline for the treatment of sarcoidosis: is the mechanism of action immunomodulating or antimicrobial effect?

Authors:  Eishi Miyazaki; Masaru Ando; Tetsujiro Fukami; Shin-Ichi Nureki; Yoshinobu Eishi; Toshihide Kumamoto
Journal:  Clin Rheumatol       Date:  2008-05-06       Impact factor: 2.980

6.  The anergic state in sarcoidosis is associated with diminished dendritic cell function.

Authors:  Sneha Mathew; Kristy L Bauer; Arne Fischoeder; Nina Bhardwaj; Stephen J Oliver
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

7.  The role of inflammation and antiinflammation therapies in keratoconjunctivitis sicca.

Authors:  Koray Gumus; Dwight H Cavanagh
Journal:  Clin Ophthalmol       Date:  2009-06-02

Review 8.  Dendritic cells in the pathogenesis of sarcoidosis.

Authors:  Lisa C Zaba; Gideon P Smith; Miguel Sanchez; Stephen D Prystowsky
Journal:  Am J Respir Cell Mol Biol       Date:  2009-04-16       Impact factor: 6.914

9.  Fungal exposure and low levels of IL-10 in patients with sarcoidosis.

Authors:  Marjeta Terčelj; Sanja Stopinšek; Alojz Ihan; Barbara Salobir; Saša Simčič; Ragnar Rylander
Journal:  Pulm Med       Date:  2014-08-07

Review 10.  Interleukin-12 family cytokines and sarcoidosis.

Authors:  Sabine Ringkowski; Paul S Thomas; Cristan Herbert
Journal:  Front Pharmacol       Date:  2014-10-27       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.